OTLK
Outlook Therapeutics, Inc.
Key Financials
Operating Income
$-67061666
↑ 6.5%
Net Income
$-62424863
↑ 17.2%
Gross Profit
$57205
N/A
Revenue
$1.4M
N/A
EPS (Diluted)
$-1.79
↑ 55.9%
Total Assets
$18.6M
↓ 35.5%
Shareholders' Equity
$-32187661.00
↑ 56.0%
Total Liabilities
$50.8M
↓ 50.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 5/18/2026 | View on SEC |
| 10-Q | 5/15/2026 | View on SEC |
| 424B5 | 5/13/2026 | View on SEC |
| 8-K | 5/13/2026 | View on SEC |
| D | 5/7/2026 | View on SEC |
| SCHEDULE 13G | 4/24/2026 | View on SEC |
| 8-K | 4/23/2026 | View on SEC |
| 424B5 | 4/23/2026 | View on SEC |
| 8-K | 4/21/2026 | View on SEC |
| 8-K | 4/7/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | OTLK |
| Company Name | Outlook Therapeutics, Inc. |
| CIK | 1649989 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 0930 |
| State of Incorporation | DE |
| Phone | 6096193990 |